secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2026-08-11T12:05:36+00:00
Accession:  0001213900-26-087506
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protara Q2 net loss $21.7M; guides ADVANCED-2 enrollment completion, THRIVE-3 interim results to 4Q 2026
--------------------------------------------------------------------------------

- Q2 2026 net loss of $21.7M ($0.36/share) vs. $15.0M ($0.35/share) in Q2 2025.
- Cash and equivalents of $161.9M at June 30, 2026; expected to fund operations into 2028.
- ADVANCED-2 BCG-Unresponsive cohort enrollment completion expected 4Q 2026; ADVANCED-3 redesigned as exploratory trial.
- STARBORN-1 showed 83% (10/12) clinical success, 100% (10/10) evaluable; BLA for TARA-002 in LMs expected 2H 2027.
- R&D expenses rose to $17.0M from $10.8M YoY; THRIVE-3 interim results expected in 4Q 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390026087506/0001213900-26-087506-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390026087506/ea0299236-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-087506

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer